Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rothrock

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Headache|September 10, 2019
Prognosis Following Discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine PatientsJason Ching, Amanda Tinsley, John Rothrock
Headache|November 4, 2010
An analysis of migraine triggers in a clinic-based populationDiane Andress-Rothrock, Wesley King, John Rothrock
Headache|April 20, 2005
Botox therapy for refractory chronic migraineStafford Conway, Curtis Delplanche, Jessica Crowder, et al.
Headache|July 13, 2010
Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcomeSilvia Weibelt, Diane Andress-Rothrock, Wesley King, et al.
Headache|October 23, 2002
Prevalence of migraine among Mexican Americans in San Diego, California: survey 1Craig A Molgaard, John Rothrock, Paul E Stang, et al.
Headache|March 16, 2007
Borderline personality disorder and migraineJohn Rothrock, Ivan Lopez, Richard Zweilfer, et al.
Medgenmed : Medscape General Medicine|October 24, 2007
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomesStephen Landy, Sarah E DeRossett, Alan Rapoport, et al.
Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.
Headache|June 3, 2022
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center studyRobert P Cowan, Alan M Rapoport, Jim Blythe, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Headache|September 10, 2019
Prognosis Following Discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine PatientsJason Ching, Amanda Tinsley, John Rothrock
Headache|November 4, 2010
An analysis of migraine triggers in a clinic-based populationDiane Andress-Rothrock, Wesley King, John Rothrock
Headache|April 20, 2005
Botox therapy for refractory chronic migraineStafford Conway, Curtis Delplanche, Jessica Crowder, et al.
Headache|July 13, 2010
Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcomeSilvia Weibelt, Diane Andress-Rothrock, Wesley King, et al.
Headache|October 23, 2002
Prevalence of migraine among Mexican Americans in San Diego, California: survey 1Craig A Molgaard, John Rothrock, Paul E Stang, et al.
Headache|March 16, 2007
Borderline personality disorder and migraineJohn Rothrock, Ivan Lopez, Richard Zweilfer, et al.
Medgenmed : Medscape General Medicine|October 24, 2007
Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomesStephen Landy, Sarah E DeRossett, Alan Rapoport, et al.
Cephalalgia : an International Journal of Headache|April 7, 2026
Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label studyJohn Rothrock, Umer Najib, Jessica Ailani, et al.
Headache|June 3, 2022
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center studyRobert P Cowan, Alan M Rapoport, Jim Blythe, et al.
Pageof 1